Abbott, Astrazeneca Signs Agreement To Co-promote Trilipix

Abbott and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott’s Trilipix (fenofibric acid). Its a medication to be used alone or in combination with a statin to treat certain lipid disorders.

Under this agreement, AstraZeneca will obtain the non-exclusive right to co-promote Trilipix alongside Abbott in the US, excluding Puerto Rico.

Jim Helm, Vice President, cardiovascular at AstraZeneca, said: “This agreement allows us to further strengthen our presence with physicians by including Trilipix as an offering to physicians for patients with dyslipidemia.

Trilipix is also used along with diet to lower triglycerides and increase HDL cholesterol in people who are at high risk of heart disease, and are taking a statin medicine to control their LDL cholesterol.